Cleave Therapeutics, Inc. Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

Cleave Biosciences, Inc. is a biotechnology research company headquartered in San Francisco, California, focused on developing therapies that target valosin-containing protein (VCP/p97). VCP/p97 is a regulator of protein homeostasis and cellular stress pathways implicated in cancer and neurodegenerative diseases, making it a strategic target for therapeutic intervention. The organization aims to exploit this biology to impair cancer cell growth and address mitochondrial health and stress factors relevant to neurodegenerative conditions, with collaborations spanning the National Cancer Institute and leading academic centers. Cleave's oncology program concentrates on inhibitors that leverage the dependency of cancer cells on VCP/p97, led by a second-generation oral compound designed to improve exposure and selectivity over earlier molecules.

It operates with a small team and serves the broader biomedical research and drug development community seeking new cancer and neurodegenerative disease therapies anchored in VCP/p97 biology. The lead candidate, CB-5339, is advancing toward a Phase 1 clinical study in acute myeloid leukemia, and the National Cancer Institute has indicated it plans to sponsor a Phase I trial in solid tumors.

Sign up for free to view info

Company overview Employee directory